Navigation Links
Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
Date:6/24/2013

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, characterizations of the results of and projected timing of clinical trials of LX4211, and the potential therapeutic and commercial potential of LX4211.  This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
2. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
3. Lexicon To Present At The Jefferies Global Healthcare Conference
4. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
6. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
7. Lexicon to Report First Quarter Financial Results on May 10, 2013
8. Lexicon To Present At The Needham Healthcare Conference
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
10. Lexicon To Present At The BIO CEO & Investor Conference
11. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 /PRNewswire/ ... CHDX ) today announced the completion of ... for $24.00 per share in cash.  Healthy Harmony is ... Ltd. ("Fosun") and Ms. Roberta Lipson , the ... merger agreement was adopted by Chindex,s stockholders at a ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014  Allakos ... additional $10 million investment from current investors to ... additional financing was completed following achievement of a ... antibody program, and represents an extension of the ... in December 2012. With this additional financing, Allakos ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre 2014 /PRNewswire/ ... Sankyo) (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ... de fusion définitif en vertu duquel Daiichi Sankyo ... en circulation d,Ambit Biosciences à 15 dollars par ... publique d,achat qui sera suivie d,une fusion avec ...
Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... OMAHA, Neb., May 15 Creighton Medical Laboratories, based ... Omaha, announced today that it has become the first ... effective testing method for cancer. The method, called SNP ... laboratories to study cancer for several years. However, Creighton ...
... , in Damaged Tissue and Cells MANDEVILLE, La., ... leading expert in the field of non-surgical skin rejuvenation ... to speed up the healing process of damaged tissue ... a double-blinded, placebo-controlled clinical study of a glycerin-based bruise-reaction ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3Glycerin Proven to Improve Bruising and Swelling Caused By Trauma to Skin 2
(Date:9/30/2014)... HealthDay Reporter MONDAY, ... should be the first choice of birth control for ... Pediatrics state. Although most U.S. teens opt for ... contraception -- intrauterine devices (IUDs) and contraceptive implants -- ... And they should be the "first-line" choices for teenage ...
(Date:9/30/2014)... Houstonians seeking the latest information about ... on the Internet. Paul Vitenas, JR. M.D., F.A.C.S., ... surgeons, has launched a new website to better inform ... Botox Cosmetic services. The new website can be ... the new website, Botox Cosmetic is a non-surgical injectable ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... caring individuals, National Children’s Oral Health Foundation: ... in grants to non-profit clinical partners. These ... Network and deliver comprehensive educational, preventive and ... Recipients include:,     Just Kids ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- For millions ... against excess weight and the threat of type 2 ... battle may be tougher for some than for others, ... promotes good health, it may not be as effective ... type 2 diabetes," said one expert, Dr. Ruth Loos, ...
(Date:9/30/2014)... 30, 2014 The global market for ... 38.75 billion by 2020 at an estimated CAGR of ... study by Grand View Research, Inc. Increasing prevalence of ... habits such as excessive alcohol consumption and growing geriatric ... is expected to serve this market as a high ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6
... the largest,provider of business services to orthodontic and ... Texas and Atlanta, Georgia to,better serve the company,s ... offices confirm our operating principle that the,heart of ... but in the,hundreds of practices we serve each ...
... INDIANAPOLIS Public health officials are constantly in ... a possible pandemic, but to fight these deadly ... need it faster. , Researchers from the Regenstrief ... have found that automated electronic medical laboratory reporting ...
... TALLAHASSEE, Fla. -- About 5,000 people around the world die ... been developed to combat it in 40 years. Researchers at ... hope to change that through research made possible by a ... award will make it possible for Timothy A. Cross, the ...
... their relatives wish to donate organs when they die, because ... protecting the body of the deceased, according to research in ... University of Southampton, UK, spoke to 26 people who had ... organ donations about their views and experiences. The 23 relatives ...
... China, Jan. 17 /Xinhua-PRNewswire-FirstCall/ -- China Nepstar,Chain ... Nepstar" or "the Company"), the,largest drugstore chain ... join the,Shenzhen Charity Federation to launch a ... health issues among low-income working women,residents in ...
... industry,s voluntary withdrawal of oral ... and cold medicines in October 2007, WASHINGTON, Jan. ... (OTC) cough and cold medicines, the Consumer Healthcare,Products Association ... Administration (FDA) decision against the use of oral OTC ...
Cached Medicine News:Health News:OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta 2Health News:Battling potential disease outbreaks online 2Health News:Researcher, magnet lab receive $2 million grant to target tuberculosis 2Health News:Relatives who decline organ donations face conflict and guilt 2Health News:Relatives who decline organ donations face conflict and guilt 3Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 2Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 3Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 4Health News:CHPA Lends Support to FDA's Announcement Against Use of Oral, Over-the-Counter Cough and Cold Medicines in Children Under Two 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: